Physician profile
Rustin Buffington
NPI 1720321946
$4,655.05
in general payments reported to CMS, 2019-2025
33 companies · $795 in 2025
The $795 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $386 · 2021: $844 · 2022: $781 · 2023: $850 · 2024: $625 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $491.05 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $449.04 | 2020-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Tris Pharma INC | $434.08 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $416.31 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Neos Therapeutics, LP | $376.63 | 2019-2023 | Cotempla Xr-Odt |
| Ironshore Pharmaceuticals INC. | $375.41 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $282.84 | 2021-2025 | |
| Kaleo, INC. | $261.02 | 2021-2023 | Auvi-Q |
| Supernus Pharmaceuticals, INC. | $227.51 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $187.70 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $172.59 | 2021-2025 | |
| Adlon Therapeutics L.P. | $121.06 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.32 | 2020-2022 | |
| Lnhc, INC | $93.56 | 2025 | Zelsuvmi |
| Alk-Abello, INC | $81.17 | 2025 | Neffy, Odactra, Grastek |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $79.66 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Nestle Healthcare Nutrition INC. | $69.29 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $57.15 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $47.09 | 2023-2025 | Daybue |
| Verrica Pharmaceuticals INC. | $41.22 | 2023-2024 | Ycanth |
| Vertical Pharmaceuticals, LLC | $39.62 | 2024-2025 | Relexxii |
| Novartis Pharmaceuticals Corporation | $37.89 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.14 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $25.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.71 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.37 | 2025 | Neffy |
| Genentech USA, INC. | $21.43 | 2020 | |
| Horizon Therapeutics Plc | $20.29 | 2022 | |
| Shire North American Group INC | $19.86 | 2019 | |
| Phadia US INC. | $18.01 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.11 | 2025 | Zoryve |
| Aytu Biopharma, INC. | $1.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rustin Buffington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.